What we do

Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.

Autolus is a leader in T-cell programming and manufacturing technology. Working in partnership with physicians and other healthcare providers, we extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which we believe will offer cancer patients substantial benefits over the existing standard of care.

Who we are

Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014.

Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cell product candidates.

Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to combat the treatment of haematological malignancies and solid tumours. Autolus believe its programmed T cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

Executive Team Board of Directors


Autolus collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates to patients.

We are actively exploring partners with complementary technologies and capabilities.

To explore a partnership with Autolus, please contact our business development team.